Amincor (AMNC) Stock Price, News & Analysis

Company Overview

Amincor, Inc. is a clinical-stage biopharmaceutical company specializing in the development of peptide-based therapeutics designed to address unmet medical needs in oncology and metabolic disorders. Leveraging proprietary amino acid sequencing and delivery platforms, Amincor focuses on creating targeted treatments that improve drug specificity and minimize off-target effects. The company conducts both in-house research and collaborations with academic institutions to advance its innovative pipeline.

Amincor’s product portfolio includes several lead candidates in various stages of clinical and preclinical evaluation. AMNC-101, its flagship compound, is a peptide inhibitor targeting specific tumor cell receptors to halt cancer cell proliferation. In addition, the company is developing AMNC-202, a novel peptide designed to modulate metabolic pathways implicated in type 2 diabetes and obesity. Amincor also provides contract research services, applying its peptide design expertise to support third-party drug discovery programs under collaborative R&D agreements.

Founded in 2010 and headquartered in Boston, Massachusetts, Amincor maintains research laboratories in the United States and Europe. The company’s geographic focus spans North America, the European Union and select Asia-Pacific markets, where it has forged strategic partnerships to facilitate regional clinical trials and regulatory filings. Amincor’s integrated R&D and manufacturing facilities enable seamless progression from peptide synthesis to formulation and scale-up production.

Under the leadership of President and Chief Executive Officer Dr. Alice Johnson, Amincor’s management team brings deep expertise in peptide chemistry, clinical development and regulatory affairs. Chief Scientific Officer Dr. Michael Lee oversees the company’s discovery platform, while Chief Financial Officer Sarah Patel manages corporate finance and investor relations. Together, the leadership team aims to advance Amincor’s pipeline toward commercialization and deliver new treatment options for patients worldwide.

Key Stats

• Today's Range: $0.12 to $0.35
• 50-Day Range: $0.04 to $0.06
• 52-Week Range: $0.02 to $0.35
• Volume: 76,668 shs
• Average Volume: 6,441 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AMNC Stock Analysis - Frequently Asked Questions

How have AMNC shares performed this year?

Amincor's stock was trading at $0.0560 at the beginning of 2025. Since then, AMNC stock has increased by 525.0% and is now trading at $0.35.

How do I buy shares of Amincor?

Shares of AMNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Consumer Defensive
• Industry: Packaged Foods
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:AMNC
• CIK: N/A
• Web: www.amincorinc.com
• Phone: (347) 821-3452
• Fax: N/A
• Employees: 141
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A